Related Experiment Video
Updated: May 5, 2026

Impression Cytology of the Lid Wiper Area
Published on: August 9, 2016
Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review
Perumal Jayaraj1, Debjeet Ray1, Kevika Goel1
1Department of Zoology, Sri Venkateswara College, University of Delhi, Delhi, India.
Abstract:
Eyelid sebaceous gland carcinoma (SGC) is an aggressive skin cancer characterized by a heightened risk of recurrence and metastasis. While surgical excision is the primary treatment, unraveling the molecular intricacies of SGC is imperative for advancing targeted therapeutic interventions and enhancing patient outcomes. This comprehensive review delves into the molecular landscape of eyelid SGC, emphasizing key genetic alterations, signaling pathways, epigenetic modifications, and potential therapeutic targets. Significant findings include aberrations in critical signaling pathways (β-catenin, lymphoid enhancer binding factor, hedgehog, epidermal growth factor receptor, P53, and P21WAF1) associated with SGC progression and poor prognosis. Notably, eyelid SGC manifests a distinctive mutational profile, lacking ultraviolet signature mutations in tumor protein 53 (TP53), indicating alternative mutagenic mechanisms. Next-generation sequencing identifies actionable mutations in genes such as phosphatase and tensin homolog (PTEN) and Erb-B2 receptor tyrosine kinase 2 (ERBB2), facilitating the emergence of personalized medicine approaches. Molecular chaperones, specifically X-linked inhibitor of apoptosis protein (XIAP) and BAG3, emerge as pivotal players in promoting tumor survival and proliferation. The review underscores the role of epithelial-mesenchymal transition, where regulators like E-cadherin, vimentin, and ZEB2 contribute to SGC aggressiveness. Epigenetic modifications, encompassing DNA methylation and microRNA dysregulation, further elucidate the molecular landscape. This review consolidates a comprehensive understanding of the molecular drivers of eyelid SGC, shedding light on potential therapeutic targets and providing a foundation for future investigations in diagnostic, prognostic, and personalized treatment strategies for this formidable malignancy.
Insights
Eyelid sebaceous gland carcinoma (SGC) is aggressive, with unique mutations. Understanding its molecular drivers, like signaling pathways and genetic alterations, is key for developing targeted therapies and improving patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Eyelid sebaceous gland carcinoma (SGC) is an aggressive skin cancer with high recurrence and metastasis rates.
- Current treatments rely on surgical excision, highlighting the need for advanced molecular insights.
- Understanding SGC's molecular basis is crucial for developing targeted therapies and improving patient prognosis.
Purpose of the Study:
- To provide a comprehensive review of the molecular landscape of eyelid SGC.
- To emphasize key genetic alterations, signaling pathways, and epigenetic modifications in SGC.
- To identify potential therapeutic targets for personalized medicine approaches.
Main Methods:
- Literature review synthesizing findings on genetic alterations, signaling pathways (e.g., β-catenin, EGFR, TP53), and epigenetic modifications.
- Analysis of next-generation sequencing data identifying actionable mutations (e.g., PTEN, ERBB2).
- Examination of the roles of molecular chaperones (XIAP, BAG3) and epithelial-mesenchymal transition (EMT) markers (E-cadherin, vimentin, ZEB2).
Main Results:
- Identified key signaling pathway aberrations (β-catenin, LEF, hedgehog, EGFR, P53, P21WAF1) linked to SGC progression and poor prognosis.
- Eyelid SGC exhibits a distinct mutational profile, lacking UV-signature TP53 mutations, suggesting alternative mutagenic pathways.
- Actionable mutations in PTEN and ERBB2 were identified, paving the way for personalized medicine.
- Molecular chaperones XIAP and BAG3, along with EMT regulators, significantly contribute to SGC survival and aggressiveness.
- DNA methylation and microRNA dysregulation were implicated as important epigenetic modifications.
Conclusions:
- A comprehensive understanding of eyelid SGC's molecular drivers, including genetic alterations, signaling pathways, and epigenetic factors, has been consolidated.
- The review highlights potential therapeutic targets and provides a foundation for future research in diagnostic, prognostic, and personalized treatment strategies.
- Targeting identified molecular pathways and genetic alterations holds promise for advancing SGC treatment and improving patient outcomes.
Related Concept Videos
The Tumor Microenvironment
Accessory Structures of the Skin: Sebaceous Glands
These glands that produce the oils on the skin and hair are holocrine glands. The mature...
Microbiome of the Eye

